A New Series of Moisture Stable Metallacyclic Heteroleptic Titanium(IV) Complexes of 8-Hydroxyquinoline: Synthesis, Characterization, Stability Study and Cytotoxicity Evaluation

BLASSAN SAMUEL^{1,*} and MADHVESH PATHAK²

¹Faculty of Education, St. Theresa International College, Bangkok-26120, Thailand

²Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore-632014, India

*Corresponding author: Fax: + 66 37 349936; E-mail: blassansamuel@gmail.com

Received: 6 April 2019;

Accepted: 4 May 2019;

Published online: 21 May 2019;

AJC-19427

A new series of moisture resistant metallacyclic titanium(IV) derivatives prepared from 8-hydroxyquinoline of the general formulae $[(Q_2)Ti\{(L_1)(L_2OR)\}]$ (**3a-b**, **3d-e**), $[(Q_2)Ti\{(L_1)(L_3)\}]$ (**3c** and **3f**) and $[(Q_2)Ti(L_4)]$ (**3g** and **3h**) is synthesized by interacting the precursor molecule $[(Q_2)Ti(OiPr)_2]$ (**2**) with various 2-heteroaryl methyl ketone oximes and various alkoxyalkanols/2-hydroxypyridine or only with catechol/resorcinol in 1:1:1 or in 1:1 molar ratios in anhydrous boiling toluene (where, HQ = 8-hydroxyquinoline; *i*Pr = isopropyl; L_1H = HONC(Me)py-2/HONC(Me)fu-2; L_2 = O-CH₂-CH₂-; R = CH₃, C₂H₅; L_3H = 2-hydroxypyridine and L_4H = catechol/resorcinol). Stability study revealed that these molecules were stable for a period of 72 h. Mononuclear nature of the complexes was confirmed through mass spectral analysis. Thermogravimetric results explain the multistage fragmentation of the complexes at 900 °C. NMR, FTIR, and UV-visible spectral data suggested that titanium-ligands attachment is in a hexa-coordinated manner. Additionally, all these molecules were tested for their tumour inhibiting potential against MDA-MB-231 human breast carcinoma cell line.

Keywords: 8-Hydroxyquinoline, Titanium complexes, Cytotoxicity evaluation, Moisture stability, Metal-to-ligand charge transfer.

INTRODUCTION

The triumph of cisplatin as a metal-containing therapeutics has opened a new avenue for the researchers for the synthesis and activity evaluation of various metal-based drugs [1-3]. Among the various metal complexes, titanium based complexes have captured the attention of researchers due to their diverse applications including their potential cytotoxic efficiency [4]. Two titanium complexes namely, budotitan and titanocene dichloride have displayed substantial tumour inhibiting potential against different cell lines [5]. However, these complexes have extremely low stability in the moisture-enriched environment [6]. This undesirable attribute rendered them in failure in the clinical trial [7].

In order to prevail the achilles heel of titanium complexes we have selected 8-hydroxyquinoline (8-HQ) as a ligand. Though several titanium-HQ complexes have already been reported [8-10], their tumour inhibiting potential has never been an area of investigation. In the present series, we have synthesized different heteroleptic titanium derivatives which are prepared

from 8-HQ and with different ketone oximes and various alkoxyalkanols or 2-hydroxypyridine or only with catechol or resorcinol. Additionally, we have studied the stability of all these molecules in the moisture-enriched environment and found that all these complexes are stable in hydrous condition for a period of 72 h.

Tumour has become one of the destructive diseases across the globe. Though various kinds of drugs are available in the market, the complete annihilation of this deadly disease is still a vexing issue [11]. Preparation of efficient cytotoxic drug is the only remedy for mitigating such a deleterious situation. Hence, we have decided to prepare various 8-HQ-titanium complexes and evaluate their tumour inhibiting efficiency against MDA-MB-231 human breast carcinoma cell line by employing cisplatin as the standard drug.

EXPERIMENTAL

All the reagents purified either by distillation or by recrystallization and prior to the experiment were dried thoroughly.

Toluene (Sd Fine Chemicals, b.p., 110.6 °C) was dried first by keeping over sodium wire for a night and later refluxed on the fractionating column for 24 h and finally it was distilled off.

Nuclear magnetic resonance: ^1H NMR data were obtained from a BRUKER Advance III NMR spectrometer in DMSO/ CDCl_3 solution at 400 MHz frequency using TMS as an internal standard. While the ^{13}C NMR spectral studies of new titanium derivatives were performed in DMSO/ CDCl_3 solution on a BRUKER Advance III NMR spectrometer at 100 MHz frequency.

Fourier transform infrared: FTIR spectra were taken on a SHIMADZU IR affinity 1 spectrometer with anhydrous KBr pellets in the range of 4000–400 cm^{-1} .

Mass spectroscopy: Mass spectral data of new titanium complexes were recorded on a HR-Q-ToF mass spectrometer.

Thermogravimetric analysis: Thermogravimetric analyses of new complexes were performed on a TA instrument SDTQ 600, USA at a heating rate of 10 °C/min from 25 °C to 900 °C under flowing nitrogen environment.

Elemental analysis: Elemental analyses of the complexes were carried out on an Elementar Vario EL III instrument.

Ultraviolet-visible spectrophotometer: The UV-visible spectra were taken over a range of 200–800 cm^{-1} using JASCO V-670 UV-Visible spectrophotometer.

Synthesis of oximes: Oximes were prepared by a reported method [12,13] and all of them were recrystallized in hot water.

Estimation of titanium and isopropanol: Estimation of titanium was carried out by a known method [14] and chromate oxidimetric method [15] employed for estimating the liberated isopropanol during the course of the reactions.

Synthesis of [*cis*-di-2-propanolato-*bis*(8-quinolinato)-titanium(IV)] (2): 8-Hydroxyquinoline (8-HQ) (1.43 g, 9.85 mmol) added to a toluene solution (30 mL) of $[\text{Ti}(\text{OPr}^i)_4]$ (1.4 g, 4.93 mmol) and the reaction mixture was refluxed for 4–5 h at 100–120 °C. The reaction progress was monitored by estimating the liberated isopropanol collected azeotropically with toluene. The excess solvent present in the reaction mixture was removed *in vacuo* to leave behind a solid (2.24 g, 4.93 mmol). It was then purified by washing with previously dried *n*-hexane. Colour: greenish yellow; m.p.: > 360 °C; Alcohol estimation (Pr^iOH): Calcd. (found): 0.592 g (0.587 g); HRMS: m/z (pos): 454.1419, $\text{C}_{24}\text{H}_{26}\text{N}_2\text{O}_4\text{Ti}$ (calcd. 454.1416); Anal. calcd. (found) % for $\text{C}_{24}\text{H}_{26}\text{N}_2\text{O}_4\text{Ti}$: C, 63.45 (63.38); H, 5.77 (5.79); N, 6.17 (6.11); Ti, 10.54 (10.41).

Synthesis of 2-acetylpyridineoximato-2-methoxyethanolato-*bis*(8-quinolinato)titanium(IV)] (3a): *cis*-di-2-propanolato-*bis*(8-quinolinato)titanium(IV) [$(\text{Q}_2)\text{Ti}(\text{OPr}^i)_2$] (2) (1.82 g, 4.00 mmol) added to a toluene solution (~40 mL) of $\text{OH-CH}_2\text{-CH}_2\text{-OCH}_3$ (0.31 g, 4.07 mmol) and 2-acetylpyridine oxime (0.55 g, 4.03 mmol). The reaction mixture was then refluxed and heated for 4–5 h at 100–120 °C. Oxidimetric titration was employed for monitoring the progress of reaction by estimating the liberated isopropanol collected azeotropically with toluene. After the completion of reaction, excess solvents were removed *in vacuo* to furnish solid product and it was finally purified by washing with dried *n*-hexane and toluene. The same route has been employed for the synthesis of other derivatives. Colour: pale yellow powder; m.p.: 260–262 °C; Yield: 98.4 %; Alcohol estimation (Pr^iOH): calcd. (found): 0.48 g (0.47 g); UV (DMSO)

λ_{max} (log ϵ): 265 (5.72), 318 (5.80) nm; IR (KBr, ν_{max} , cm^{-1}): 2939, 2908, 2894, 1600, 1579, 1491, 1460, 1385, 1311, 1263, 1114, 968, 822, 788, 740, 738, 619, 440; ^1H NMR (400 MHz, CDCl_3) δ : 8.54 (2H, dd, J = 1.6, 8.0 Hz, H-2, H-2'), 8.24 (2H, dd, J = 1.6, 8.0 Hz, H-4, H-4'), 7.78 (2H, dd, J = 1.6, 8.0 Hz, H-5, H-5'), 7.60 (2H, dd, J = 1.6, 8.0 Hz, H-6, H-6'), 7.56 (2H, dd, J = 1.6, 8.0 Hz, H-3, H-3'), 7.17 (2H, dd, J = 1.6, 8.0 Hz, H-7, H-7'), 6.74 (1H, t, H-4''), 6.48 (1H, t, H-5''), 6.44 (1H, d, J = 7.6 Hz, H-6''), 6.28 (1H, d, J = 7.6 Hz, H-3''), 4.72 (2H, t, $-\text{OCH}_2$), 4.25 (2H, t, $-\text{CH}_2\text{O}$), 3.36 (3H, s, $-\text{OCH}_3$), 2.91 (3H, s, H-1'''); ^{13}C NMR (100 MHz, CDCl_3) δ : 155.7 (C, C-2''), 153.3 (C, C-2'''), 151.7 (C, C-8, C-8'), 149.4 (CH, C-2, C-2'), 148.3 (CH, C-6''), 136.0 (CH, C-4''), 132.1 (C, C-8a, C-8a'), 130.5 (CH, C-4, C-4'), 129.2 (C, C-4a, C-4a'), 128.9 (CH, C-6, C-6'), 126.5 (CH, C-3, C-3'), 123.5 (CH, C-5''), 122.9 (CH, C-3''), 121.6 (CH, C-5, C-5'), 117.1 (CH, C-7, C-7'), 75.8 (CH_2 , $-\text{OCH}_2$), 72.8 (CH_2 , $-\text{CH}_2\text{O}$), 61.5 (CH_3 , OCH_3), 15.7 (CH_3 , C-1'''); HRMS: m/z (pos): 546.1390, $\text{C}_{28}\text{H}_{26}\text{N}_4\text{O}_5\text{Ti}$ (calcd. 546.1383); Anal. calcd. (found) % for $\text{C}_{28}\text{H}_{26}\text{N}_4\text{O}_5\text{Ti}$: C, 61.55 (61.72); H, 4.80 (4.73); N, 10.25 (10.30); Ti, 8.76 (8.51).

[2-Acetylpyridineoximato-2-ethoxyethanolato-*bis*(8-quinolinato)titanium(IV)] (3b): Colour: Pale yellow powder; Yield: 97.9 %; Alcohol estimation (Pr^iOH): calcd. (found): 0.47 g (0.46 g); UV (DMSO) λ_{max} (log ϵ): 267 (5.72), 316 (5.80) nm; IR (KBr, ν_{max} , cm^{-1}): 2941, 2912, 2848, 1602, 1575, 1498, 1467, 1379, 1321, 1273, 1109, 960, 825, 785, 744, 734, 624, 482; ^1H NMR (400 MHz, CDCl_3) δ : 8.57 (2H, dd, J = 1.6, 8.0 Hz, H-2, H-2'), 8.26 (2H, dd, J = 1.6, 8.0 Hz, H-4, H-4'), 7.62 (2H, dd, J = 1.6, 8.0 Hz, H-5, H-5'), 7.58 (2H, dd, J = 1.6, 8.0 Hz, H-6, H-6'), 7.18 (2H, dd, J = 1.6, 8.0 Hz, H-3, H-3'), 7.02 (2H, dd, J = 1.6, 8.0 Hz, H-7, H-7'), 6.67 (1H, t, H-4''), 6.46 (1H, t, H-5''), 6.29 (1H, d, J = 7.6 Hz, H-6''), 6.23 (1H, d, J = 8.0 Hz, H-3''), 4.53 (2H, t, $-\text{OCH}_2$), 4.04 (2H, t, $-\text{CH}_2\text{O}$), 3.45 (2H, q, $-\text{CH}_2\text{CH}_3$), 2.25 (3H, s, H-1'''), 1.16 (3H, t, $-\text{CH}_2\text{CH}_3$); ^{13}C NMR (100 MHz, CDCl_3) δ : 154.3 (C, C-2''), 152.7 (C, C-2'''), 151.7 (C, C-8, C-8'), 150.0 (CH, C-2, C-2'), 148.4 (CH, C-6''), 136.0 (CH, C-4''), 134.2 (C, C-8a, C-8a'), 132.5 (CH, C-4, C-4'), 130.9 (C, C-4a, C-4a'), 128.7 (CH, C-6, C-6'), 126.6 (CH, C-3, C-3'), 123.5 (CH, C-5''), 122.1 (CH, C-3''), 121.6 (CH, C-5, C-5'), 117.1 (CH, C-7, C-7'), 75.3 (CH_2 , $-\text{OCH}_2$), 70.5 (CH_2 , $-\text{CH}_2\text{O}$), 68.9 (CH_2 , $-\text{OCH}_2\text{CH}_3$), 17.8 (CH_3 , $-\text{OCH}_2\text{CH}_3$), 15.2 (CH_3 , C-1'''); HRMS: m/z (pos): 560.1542, $\text{C}_{29}\text{H}_{28}\text{N}_4\text{O}_5\text{Ti}$ (calcd. 560.1539); Anal. calcd. (found) % for $\text{C}_{29}\text{H}_{28}\text{N}_4\text{O}_5\text{Ti}$: C, 62.15 (62.04); H, 5.04 (5.13); N, 10.01 (10.15); Ti, 8.54 (8.41).

[2-Acetylpyridineoximato-2-pyridineato-*bis*(8-quinolinato)titanium(IV)] (3c): Colour: pale yellow powder; Yield: 98.1; Alcohol estimation (Pr^iOH): calcd. (found): 0.44 g (0.43 g); UV (DMSO) λ_{max} (log ϵ): 264 (5.72), 311 (5.79) nm; IR (KBr, ν_{max} , cm^{-1}): 2954, 2916, 2843, 1651, 1602, 1575, 1541, 1498, 1469, 1377, 1271, 1236, 1155, 1107, 993, 825, 800, 731, 619, 437; ^1H NMR (400 MHz, CDCl_3) δ : 8.58 (2H, dd, J = 1.6, 8.0 Hz, H-2, H-2'), 7.92 (2H, dd, J = 1.6, 8.0 Hz, H-4, H-4'), 7.77 (2H, dd, J = 1.6, 8.0 Hz, H-5, H-5'), 7.43 (2H, dd, J = 1.6, 8.0 Hz, H-6, H-6'), 7.39 (2H, dd, J = 1.6, 8.0 Hz, H-3, H-3'), 7.35 (2H, dd, J = 1.6, 8.0 Hz, H-7, H-7'), 7.28 (1H, d, J = 8.0 Hz, H-6''), 7.24 (1H, d, J = 8.0 Hz, H-3''), 7.18 (1H, d, J = 8.0

Hz, H-6*), 7.11 (1H, t, H-4*), 6.98 (1H, dd, $J = 1.2, 7.6$ Hz, H-4''), 6.36 (1H, d, $J = 8.0$ Hz, H-3*), 6.31 (1H, dd, $J = 1.6, 8.0$ Hz, H-5''), 6.17 (1H, t, H-5*), 2.36 (3H, s, H-1'''); ^{13}C NMR (100 MHz, CDCl_3) δ : 156.5 (C, C-2*), 153.5 (C, C-2''), 151.4 (C, C-2''), 149.4 (CH, C-6''), 147.8 (C, C-8, C-8'), 146.0 (CH, C-4*), 145.2 (CH, C-2, C-2'), 139.8 (C, C-8a, C-8a'), 136.0 (CH, C-4''), 133.3 (CH, C-5''), 131.6 (CH, C-4, C-4'), 128.9 (C, C-4a, C-4a'), 127.6 (CH, C-6, C-6'), 125.5 (CH, C-6*), 123.6 (CH, C-3, C-3'), 122.6 (CH, C-3''), 121.7 (CH, C-5, C-5'), 119.2 (CH, C-3*), 117.8 (CH, C-7, C-7'), 102.3 (CH, C-5*), 15.9 (CH_3 , C-1'''); HRMS: m/z (pos): 565.1236, $\text{C}_{30}\text{H}_{23}\text{N}_5\text{O}_4\text{Ti}$ (calcd. 565.1230); Anal. calcd. (found) % for $\text{C}_{30}\text{H}_{23}\text{N}_5\text{O}_4\text{Ti}$: C, 63.73 (63.87); H, 4.11 (4.21); N, 12.39 (12.33); Ti, 8.47 (8.62).

[2-Acetylfuranoximato-2-methoxyethanolato-bis(8-quinolinato)titanium(IV)] (3d): Colour: pale yellow powder; Yield: 98.7 %; Alcohol estimation (Pr^iOH): calcd. (found): 0.49 g (0.48 g); UV (DMSO) λ_{max} (log ϵ): 266 (5.72), 320 (5.80) nm; IR (KBr, ν_{max} , cm^{-1}): 2933, 2907, 2846, 1575, 1498, 1467, 1382, 1323, 1276, 1228, 1163, 1109, 1018, 910, 823, 744, 715, 624, 426; ^1H NMR (400 MHz, CDCl_3) δ : 8.30 (2H, dd, $J = 1.6, 8.0$ Hz, H-2, H-2'), 7.97 (2H, dd, $J = 1.6, 8.0$ Hz, H-4, H-4'), 7.60 (2H, dd, $J = 1.6, 8.0$ Hz, H-5, H-5'), 7.39 (2H, dd, $J = 1.6, 8.0$ Hz, H-6, H-6'), 7.09 (2H, dd, $J = 1.6, 8.0$ Hz, H-3, H-3'), 7.03 (2H, dd, $J = 1.6, 8.0$ Hz, H-7, H-7'), 6.48 (1H, d, $J = 8.0$ Hz, H-5*), 5.96 (1H, t, H-4*), 5.79 (1H, d, $J = 8.0$ Hz, H-3*), 3.66 (2H, t, $-\text{OCH}_2$), 3.43 (2H, t, $-\text{CH}_2\text{O}$), 3.32 (3H, s, $-\text{OCH}_3$), 2.18 (3H, s, H-1'''); ^{13}C NMR (100 MHz, CDCl_3) δ : 155.3 (C, C-2''), 150.8 (C, C-8, C-8'), 149.4 (CH, C-2, C-2'), 146.7 (C, C-2*), 143.9 (CH, C-5*), 136.1 (C, C-8a, C-8a'), 133.1 (CH, C-4, C-4'), 131.5 (C, C-4a, C-4a'), 129.9 (CH, C-6, C-6'), 128.8 (CH, C-3, C-3'), 126.6 (CH, C-5, C-5'), 122.6 (CH, C-4*), 121.1 (CH, C-7, C-7') 117.2 (CH, C-3*), 78.0 (CH_2 , $-\text{OCH}_2$), 72.9 (CH_2 , $-\text{CH}_2\text{O}$), 61.6 (CH_3 , OCH_3), 15.0 (CH_3 , C-1''); HRMS: m/z (pos): 535.1225, $\text{C}_{27}\text{H}_{25}\text{N}_3\text{O}_6\text{Ti}$ (calcd. 535.1223); Anal. calcd. (found) % for $\text{C}_{27}\text{H}_{25}\text{N}_3\text{O}_6\text{Ti}$: C, 60.57 (60.58); H, 4.71 (4.60); N, 7.85 (8.06); Ti, 8.94 (9.03).

[2-Acetylfuranoximato-2-ethoxyethanolato-bis(8-quinolinato)titanium(IV)] (3e): Colour: pale yellow powder; Yield: 98.2 %; Alcohol estimation (Pr^iOH): calcd. (found) 0.43 g (0.42 g); UV (DMSO) λ_{max} (log ϵ): 268 (5.73), 321 (5.81) nm; IR (KBr, ν_{max} , cm^{-1}): 2930, 2913, 2854, 1708, 1602, 1575, 1498, 1469, 1379, 1323, 1276, 1230, 1163, 1109, 1018, 910, 810, 783, 744, 715, 619, 418; ^1H NMR (400 MHz, CDCl_3) δ : 8.30 (2H, dd, $J = 1.6, 8.0$ Hz, H-2, H-2'), 7.59 (2H, dd, $J = 1.6, 8.0$ Hz, H-4, H-4'), 7.34 (2H, dd, $J = 1.6, 8.0$ Hz, H-5, H-5'), 7.22 (2H, dd, $J = 1.6, 8.0$ Hz, H-6, H-6'), 6.51 (2H, dd, $J = 1.6, 8.0$ Hz, H-3, H-3'), 6.47 (1H, d, $J = 8.4$ Hz, H-5*), 6.37 (1H, t, H-4*), 5.95 (2H, dd, $J = 1.6, 8.0$ Hz, H-7, H-7'), 5.79 (1H, d, $J = 8.0$ Hz, H-3*), 3.66 (2H, t, $-\text{OCH}_2$), 3.49 (2H, t, $-\text{CH}_2\text{O}$), 3.46 (2H, q, $-\text{CH}_2\text{CH}_3$), 2.26 (3H, s, H-1''), 1.15 (3H, t, $-\text{CH}_2\text{CH}_3$); ^{13}C NMR (100 MHz, CDCl_3) δ : 155.9 (C, C-2''), 153.2 (C, C-2*), 151.8 (C, C-8, C-8'), 149.4 (CH, C-2, C-2'), 144.7 (CH, C-5*), 134.1 (C, C-8a, C-8a'), 132.5 (CH, C-4, C-4'), 130.9 (C, C-4a, C-4a'), 128.8 (CH, C-6, C-6'), 126.6 (CH, C-3, C-3'), 121.6 (CH, C-5, C-5'), 118.8 (CH, C-4*), 117.2 (CH, C-7, C-7'), 112.0 (CH, C-3*), 75.4 (CH_2 , $-\text{OCH}_2$), 70.5 (CH_2 , $-\text{CH}_2\text{O}$), 68.9 (CH_2 , OCH_2CH_3), 17.3 (CH_3 , $-\text{OCH}_2\text{CH}_3$), 15.2 (CH_3 , C-1''); HRMS: m/z (pos): 549.1384, $\text{C}_{28}\text{H}_{27}\text{N}_3\text{O}_6\text{Ti}$ (calcd. 549.1379);

Anal. calcd. (found) % for $\text{C}_{28}\text{H}_{27}\text{N}_3\text{O}_6\text{Ti}$: C, 61.21 (61.24); H, 4.95 (4.81); N, 7.65 (7.73); Ti, 8.71 (8.52).

[2-Acetylfuranoximato-2-pyridineato-bis(8-quinolinato)titanium(IV)] (3f): Colour: pale yellow powder; Yield: 97.8 %; Alcohol estimation (Pr^iOH): calcd. (found): 0.45 g (0.44 g); UV (DMSO) λ_{max} (log ϵ): 265 (5.46), 312 (5.53) nm; IR (KBr, ν_{max} , cm^{-1}): 2934, 2917, 2851, 1649, 1602, 1575, 1498, 1467, 1379, 1321, 1274, 1109, 1016, 910, 821, 783, 742, 715, 436; ^1H NMR (400 MHz, CDCl_3) δ : 8.29 (2H, dd, $J = 1.2, 8.4$ Hz, H-2, H-2'), 7.65 (2H, dd, $J = 1.6, 8.0$ Hz, H-4, H-4'), 7.44 (2H, dd, $J = 1.6, 8.0$ Hz, H-5, H-5'), 7.39 (2H, dd, $J = 1.6, 8.0$ Hz, H-6, H-6'), 7.20 (1H, t, H-4*), 7.01 (1H, d, $J = 7.6$ Hz, H-5*), 6.56 (1H, t, H-5*), 6.53 (1H, d, $J = 4.0$ Hz, H-6*), 6.47 (1H, d, $J = 8.0$ Hz, H-3*), 6.38 (2H, dd, $J = 1.6, 8.0$ Hz, H-3, H-3'), 6.29 (1H, dt, H-4*), 5.94 (2H, dd, $J = 1.6, 8.0$ Hz, H-7, H-7'), 5.76 (1H, d, $J = 8.0$ Hz, H-3*), 2.17 (3H, s, H-1'''); ^{13}C NMR (100 MHz, CDCl_3) δ : 158.7 (C, C-2*), 156.5 (C, C-2''), 149.3 (C, C-2*), 148.8 (C, C-8, C-8'), 147.1 (CH, C-5*), 145.2 (CH, C-2, C-2'), 144.7 (CH, C-4*), 139.8 (C, C-8a, C-8a'), 137.3 (CH, C-6*), 133.3 (CH, C-3*), 130.6 (CH, C-4, C-4'), 126.9 (C, C-4a, C-4a'), 124.6 (CH, C-6, C-6'), 122.7 (CH, C-3, C-3'), 121.7 (CH, C-5, C-5'), 119.8 (CH, C-7, C-7') 118.5 (CH, C-5*), 112.2 (CH, C-4*), 102.3 (CH, C-3*), 15.6 (CH_3 , C-1''); HRMS: m/z (pos): 554.1077, $\text{C}_{29}\text{H}_{22}\text{N}_4\text{O}_5\text{Ti}$ (calcd. 554.1070); Anal. calcd. (found) % for $\text{C}_{29}\text{H}_{22}\text{N}_4\text{O}_5\text{Ti}$: C, 62.83 (62.63); H, 4.04 (4.22); N, 10.11 (10.03); Ti, 8.63 (8.95).

[Benzene-1,2-diolato-bis(8-quinolinato)titanium(IV)] (3g): Colour: Chocolate brown powder; Yield: 98.3 %; Alcohol estimation (Pr^iOH): calcd. (found) 0.47 g (0.46 g); UV (DMSO) λ_{max} (log ϵ): 263 (5.37), 316 (5.45) nm; IR (KBr, ν_{max} , cm^{-1}): 2940, 2921, 2856, 1602, 1573, 1496, 1463, 1375, 1315, 1109, 767, 750, 644, 422; ^1H NMR (400 MHz, CDCl_3) δ : 8.87 (2H, dd, $J = 1.6, 8.0$ Hz, H-2, H-2'), 8.38 (1H, d, $J = 7.6$ Hz, H-3*), 7.58 (2H, dd, $J = 1.6, 8.0$ Hz, H-4, H-4'), 7.47 (1H, t, H-4*), 7.42 (2H, dd, $J = 1.6, 8.0$ Hz, H-5, H-5'), 7.25 (1H, t, H-5*), 7.17 (1H, d, $J = 7.6$ Hz, H-6*), 7.12 (2H, dd, $J = 1.6, 8.0$ Hz, H-6, H-6'), 6.73 (2H, dd, $J = 1.6, 8.0$ Hz, H-3, H-3'), 6.60 (2H, dd, $J = 1.6, 8.0$ Hz, H-7, H-7'); ^{13}C NMR (100 MHz, CDCl_3) δ : 152.4 (C, C-8, C-8'), 148.2 (CH, C-2, C-2'), 145.2 (C, C-1^s, C-2^s), 132.4 (C, C-8a, C-8a'), 130.9 (CH, C-4, C-4'), 129.9 (C, C-4a, C-4a'), 127.9 (CH, C-6, C-6'), 126.5 (CH, C-3, C-3'), 125.0 (CH, C-5, C-5'), 123.4 (CH, C-4^s, C-5^s), 121.1 (CH, C-7, C-7'), 117.2 (CH, C-6^s, C-3^s); HRMS: m/z (pos): 444.0594, $\text{C}_{24}\text{H}_{16}\text{N}_2\text{O}_4\text{Ti}$ (calcd. 444.0590); Anal. calcd. (found) % for $\text{C}_{24}\text{H}_{16}\text{N}_2\text{O}_4\text{Ti}$: C, 64.88 (64.90); H, 3.63 (3.64); N, 6.31 (6.61); Ti, 10.77 (10.74).

[Benzene-1,3-diolato-bis(8-quinolinato)titanium(IV)] (3h): Colour: reddish brown powder; Yield: 98.6 %; Alcohol estimation (Pr^iOH): calcd. (found): 0.44 g (0.43 g); UV (DMSO) λ_{max} (log ϵ): 262 (5.37), 318 (5.46) nm; IR (KBr, ν_{max} , cm^{-1}): 2946, 2926, 2861, 1573, 1496, 1463, 1375, 1321, 1301, 1269, 1166, 1134, 1107, 977, 852, 744, 630, 426; ^1H NMR (400 MHz, CDCl_3) δ : 8.50 (2H, dd, $J = 1.6, 8.0$ Hz, H-2, H-2'), 8.25 (2H, dd, $J = 1.6, 8.0$ Hz, H-4, H-4'), 7.24 (2H, dd, $J = 1.6, 8.0$ Hz, H-5, H-5'), 7.15 (2H, dd, $J = 1.6, 8.0$ Hz, H-6, H-6'), 7.06 (1H, d, $J = 8.0$ Hz, H-4*), 6.94 (1H, s, H-2^s), 6.81 (2H, dd, $J = 1.6, 8.0$ Hz, H-3, H-3'), 6.23 (1H, d, $J = 8.0$ Hz, H-6*), 6.20 (1H, dd, $J = 1.6, 8.0$ Hz, H-5*), 6.13 (2H, dd, $J = 1.6, 8.0$

Hz, H-7, H-7'); ^{13}C NMR (100 MHz, CDCl_3) δ : 149.7 (C, C-8, C-8'), 147.6 (CH, C-2, C-2'), 145.9 (C, C-1^s, C-3^s), 137.9 (C, C-8a, C-8a'), 136.3 (CH, C-4, C-4'), 135.3 (CH, C-5^s), 130.8 (C, C-4a, C-4a'), 129.2 (CH, C-6, C-6'), 126.2 (CH, C-3, C-3'), 124.4 (CH, C-5, C-5'), 123.8 (CH, C-4^s, C-6^s), 120.9 (CH, C-7, C-7'), 95.9 (CH, C-2^s); HRMS: m/z (pos): 444.0598, $\text{C}_{24}\text{H}_{16}\text{N}_2\text{O}_4\text{Ti}$ (calcd. 444.0590); Anal. calcd. (found) % for $\text{C}_{24}\text{H}_{16}\text{N}_2\text{O}_4\text{Ti}$: C, 64.88 (64.94); H, 3.63 (3.72); N, 6.31 (6.33); Ti, 10.77 (10.55).

Cytotoxicity: The study was performed on MDA-MB-231 human breast carcinoma cell line. The cell line was obtained from National Centre for Cell Science (Pune, India). The cells were maintained in L-15 (Leibovitz's) culture medium with 10 % fetal bovine serum in a humidified atmosphere at 37 °C. The cell line was maintained in their growing phase at 70 % confluency with regular passaging.

Cytotoxic potential of titanium derivatives was tested using MTT assay. MDA-MB-231 cells cultured in the culture medium (with 10 % serum), were seeded (200 μL , 6×10^3 cells/well) in a 96-well plate and incubated at 37 °C for 24 h. After incubation, the control wells were replenished with fresh medium and the test wells were treated with 25, 50 and 100 $\mu\text{g/mL}$ of complexes. The cells were further incubated for 72 h maintaining the same conditions. After the treatment incubation period, medium in each well was replenished with 200 μL of fresh medium plus 50 μL of MTT (0.6 mg/mL containing 25 μM PMS). The plate was then re-incubated for 4 h in the same conditions after which the absorbance was measured at 450 nm (with a 630 nm reference filter) in a Dynex Opsys MRTM Microplate Reader (Dynex Technologies, VA, USA). All assays were carried out in duplicate. Percentage cytotoxicity was calculated by the following formula:

$$\text{Cytotoxicity (\%)} = \frac{A_c - A_t}{A_t} \times 100$$

where, A_c is the mean absorbance of the control wells and A_t is the mean absorbance of test wells with a particular extract dosage.

RESULTS AND DISCUSSION

All the new titanium(IV) derivatives have been subjected for elemental analysis and their results are matched with the theoretical values. The elemental analyses results are the direct proof for the mononuclear nature of all these new complexes.

Treatment of titanium tetraisopropoxide $[\text{Ti}(\text{OPr}^i)_4]$ (1) with 8-hydroxyquinoline (HQ) in 1:2 mole ratio in anhydrous toluene yields $(\text{Q}_2)\text{Ti}(\text{OPr}^i)_2$ (2). The precursor molecule (1) reacted with a mixture of 2-heteroaryl methyl ketone oximes and alkoxyalkanols or 2-hydroxypyridine in 1:1:1 molar ratios gives mononuclear titanium complexes of general formulae $[(\text{Q}_2)\text{Ti}\{(\text{L}_1)(\text{L}_2\text{OR})\}]$, $[(\text{Q}_2)\text{Ti}\{(\text{L}_1)(\text{L}_3)\}]$ and $[(\text{Q}_2)\text{Ti}(\text{L}_4)]$ as given in **Scheme-I**.

The reaction progress was assessed by determining the liberated isopropanol in toluene-isopropanol azeotrope by oxidimetric titration. The reactions were very rapid and got over in 4-5 h. The products obtained were orange/yellow powder in quantitative yield. All these derivatives are sparingly soluble in common organic solvents except in CHCl_3 and DMSO and can be purified with anhydrous *n*-hexane and toluene. Based on the mass spectra and elemental analysis data, the monomeric nature of all new derivatives has been confirmed (structure of different ligands used for the synthesis is presented in Table-1).

NMR analysis: The NMR data of the new derivatives have been explained by examining it with the free spectra of the ligands used for the preparation [16,17]. The hydroxyl signal of oximes, alkoxyalkanols, dihydric phenols and 2-hydroxypyridine are observed in the region δ 8.35-10.50 ppm. The absence of these signals in the above region is the true evidence of deprotonation of hydroxyl group as well as the development of new Ti-O and Ti-N bond. The δ values of other protons as well as carbons are obtained in the expected range.

IR analysis: IR spectral interpretations of all new complexes have been carried out by matching it with the free ligand

[Where, HQ = 8-hydroxyquinoline; Pr^i = isopropyl; L_1H = HONC(Me)py-2, HONC(Me)fu-2; L_2 = O- CH_2 - CH_2 -; R = CH_3 , C_2H_5 ; L_3H = 2-hydroxypyridine and L_4H = catechol, resorcinol]

Scheme-I

TABLE-1
VARIOUS LIGANDS USED FOR THE
SYNTHESIS OF VARIOUS DERIVATIVES

Complex No.	L ₁	L ₂
3a		OHCH ₂ CH ₂ OCH ₃
3b		OHCH ₂ CH ₂ OC ₂ H ₅
3c
3d		OHCH ₂ CH ₂ OCH ₃
3e		OHCH ₂ CH ₂ OC ₂ H ₅
3f
Complex No.	L ₄	-
3g		-
3h		-

spectra [8,16,18]. The appearance of a couple of peaks in the range 2931-2849 cm⁻¹ is due to the presence of alkoxyalkanol moiety in the complexes. Lack of any peak in the range 3500-3300 cm⁻¹ is the direct evidence for the deprotonation of hydroxyl groups from various ligands used for the process of synthesis. The existence of two new peaks in the region 630-618 and 485-435 cm⁻¹ confirmed the formation of Ti-O and Ti-N bonds. Additionally, just as our expectation, a peak has been observed at 1705-1695 cm⁻¹ for two molecules (3c & 3f) as the signature of $\nu(\text{C=O})$ stretching frequency in the molecule.

Thermal analysis: Thermal stability as well as the decomposition pattern of new titanium derivatives has been evaluated by employing thermogravimetric analyses at 900 °C. Analyses have been carried out for three representative molecules (3b, 3g and 3h). All the molecules have undergone multiple stages of weight loss due to the decomposition of organic components. In case of complex 3b, aliphatic residue undergoes dissociation at 269.57 °C and the complex suffered a weight loss of 15.75 % against the theoretical value of 16.10 %. The second decomposition happened at a temperature of 392.73 °C and it is because of the dissociation of pyridine moiety present in the complex. Weight loss occurred at this stage was 22.85 % and the corresponding theoretical value was 24.10 %. The third and final decomposition of complex took place at 490.82 °C and this is due to the pyrolysis of quinoline rings of the complex. The weight loss observed at this stage was 46.20 % and the expected

value at this stage was 45.73 %. Residual TiO₂ was found as 15.2 % and the corresponding theoretical value was 14.07 %. The residual TiO₂ values for other complexes are 16.84 % (complex 3g) and 16.65 (complex 3h) against their theoretical value of 17.98 %.

UV-visible analysis: Dimethyl sulfoxide was employed in order to record the UV-visible spectra of the complexes. Each and every derivative displayed multiple absorption bands. The first λ -maximum is due to the n- π^* transition and the bands observed in the range of 305-325 nm arose due to the ligand to metal charge transfer (LMCT) band [19,20].

Mass analysis: High-resolution mass spectra were recorded for all the new titanium(IV) derivatives. The analysis report closely matches with their theoretical values and indicates the mono nuclearity of these derivatives.

Stability studies: One of the major limitations of Ti(IV) complexes including the well-known tumour inhibiting complexes such as budotitane and titanocene dichloride is their low stability in water enriched environment. The lack of stability of titanium complexes in a moisture environment is owing to the oxophilicity of titanium metal which causes the depletion of both inorganic as well as organic moieties [20]. UV-visible spectrometer was employed in order to assess the stability of the newly synthesized complexes. A band observed at 305-325 nm, indicates the LMCT band which does not turn to zero even after 72 h in hydrous condition. There was neither appearance of any new band nor slight shifting too in the existing peaks was observed during the course of the study. But, there were some visible changes in the absorbance, which is presumably due to the slow decomposition of the complex compared to rapid hydrolysis of other titanium complexes. The exceptional stability of titanium(IV) complexes is due to the formation of short Ti-N coordination bond [20] which is absent in the case of metallocene as well as β -diketonato complexes. Fig. 1 represents the UV-visible absorption overtime for the complex 3d.

Fig. 1. UV-visible absorption overtime for 2-acetyl-5-furanoximate-2-methoxyethanolato-bis(8-quinolinato)titanium(IV)] (3d) upon addition of water

Cytotoxicity evaluation: Newly synthesized titanium(IV) derivatives were subjected to cytotoxicity evaluation. The

cytotoxicity potential of titanium complexes was evaluated according to reported procedures [21,22]. The study was performed on MDA-MB-231 human breast carcinoma cell line. In this series, a few molecules displayed good antiproliferative activity. Moderate activity was observed for the remaining molecules. Complex **3h** was identified as the highest tumour inhibiting molecule among all its derivatives and its cytotoxic potential was found to be 0.05 μM against 0.017 μM of a well-known tumour inhibiting drug cisplatin [23]. The highest cytotoxic property of this molecule is due to its excellent symmetric arrangement [24]. The lower cytotoxic potential of complexes **3a** and **3b** is probably due to the presence of large steric groups in the complex. Nevertheless, complex **3c** exhibited good anti-tumor activity and its greater inhibiting potential is presumably due to the presence of one extra pyridine ring in the complex, which is absent in the former two complexes.

The tumour inhibiting potential of complexes **3d** and **3e** are also not promising. Because of bulkier groups, tumour inhibiting potentials of these complexes are decreased substantially. However, these complexes have more cytotoxic potential than their pyridine analogues. This variation in the cytotoxicity is presumably due to the lower steric strain of 5-membered cyclopentadienyl group compared to 6-membered pyridine moiety. Lower steric strain and the presence of a potential 5-membered furanyl ring make the complex **3f** more potent than its other analogue molecules. Though complex **3h** is the position isomer of molecule **3g**, their symmetry difference caused complex **3h** is more potent than its isomer. The cytotoxicity values obtained for the complexes (**3a-h**) are depicted in Table-2.

TABLE-2
CYTOTOXICITY VALUES OBTAINED
FOR THE COMPLEXES (**3a-h**)

Complex No.	IC ₅₀ (μM)	Complex No.	IC ₅₀ (μM)
3a	0.2902 $\pm$ 0.0036	3f	0.0796 $\pm$ 0.0047
3b	0.3095 $\pm$ 0.0077	3g	0.0623 $\pm$ 0.0071
3c	0.1348 $\pm$ 0.0018	3h	0.0503 $\pm$ 0.0026
3d	0.2685 $\pm$ 0.0022	Cisplatin	0.0166 $\pm$ 0.0047
3e	0.2869 $\pm$ 0.0039	—	—

Conclusion

The stability studies results confirm the enhanced stability of newly synthesized titanium complexes. Additionally, neither was there formation of any new peak nor decomposition of any band during the course of 72 h of study. Thus, a ligand to metal charge transfer theory has supported our results and was confirmed through UV-visible spectral studies. The deprotonation of ligands and bonding of titanium through heteroatoms have been identified by IR and NMR spectra. Elemental analyses results and the TGA fragmentation patterns are in agreement with the theoretical values. Mass spectral analyses results proposed mono-nuclearity for all these derivatives. Therefore, based on the spectral data and available literature [9,10], we have proposed a hexacoordinated *cis* octahedral geometry for these derivatives. Fig. 2 represents the proposed structures of the newly synthesized titanium(IV) complexes synthesized from 8-hydroxyquinoline, 2-hydroxypyridine, alkoxyalkanols and 2-heteroaryl methyl ketone oximes.

Fig. 2. Proposed structures of the titanium(IV) derivatives

ACKNOWLEDGEMENTS

The authors thank St. Theresa International College, Bangkok, Thailand and Vellore Institute of Technology, Vellore, India for providing necessary facilities to carry out this project work.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interests regarding the publication of this article.

REFERENCES

- E. Younes, P. Sanjiv and G.R. Santiago, *Inorganics*, **5**, 4 (2017); <https://doi.org/10.3390/inorganics5010004>.
- B.K. Keppler, C. Friesen, H.G. Moritz, H. Vongerichten and E. Vogel, Tumor-Inhibiting Bis(β -diketonato) Metal Complexes. Budotitane, *cis*-diethoxybis(1-phenylbutane-1,3-dionato)titanium(IV), In: *Bioinorganic Chemistry; Structure and Bonding*, Springer: Berlin, Heidelberg, vol. 78 (1991).
- P. Koepf-Maier and H. Koepf, *Chem. Rev.*, **87**, 1137 (1987); <https://doi.org/10.1021/cr00081a012>.
- A. Tzuberly, N. Melamed-Book and E.Y. Tshuva, *Dalton Trans.*, **47**, 3669 (2018); <https://doi.org/10.1039/C7DT04828A>.
- N. Ganot, B. Redko, G. Gellerman and E.Y. Tshuva, *RSC Adv.*, **5**, 7874 (2015); <https://doi.org/10.1039/C4RA13484B>.
- A. Tzuberly and E.Y. Tshuva, *Eur. J. Inorg. Chem.*, **2017**, 1695 (2017); <https://doi.org/10.1002/ejic.201601200>.
- S. Meker, O. Braitbard, M.D. Hall, J. Hochman and E.Y. Tshuva, *Chem. Eur. J.*, **22**, 9986 (2016); <https://doi.org/10.1002/chem.201601389>.
- B. Samuel, K.R. Ethiraj and M. Pathak, *Med. Chem. Res.*, **24**, 1504 (2015); <https://doi.org/10.1007/s00044-014-1234-3>.
- W.F. Zeng, Y.S. Chen, M.Y. Chiang, S.S. Chern and C.P. Cheng, *Polyhedron*, **21**, 1081 (2002); [https://doi.org/10.1016/S0277-5387\(02\)00873-2](https://doi.org/10.1016/S0277-5387(02)00873-2).
- W.F. Zeng, Y.H. Chen, M.Y. Chiang and C.P. Cheng, *Polyhedron*, **26**, 1303 (2007); <https://doi.org/10.1016/j.poly.2006.10.048>.
- F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel and L.A. Torre and A. Jemal, *CA: Cancer J. Clin.*, **68**, 394 (2018); <https://doi.org/10.3322/caac.21492>.
- D.L. Gamble, W.P. Hems and B. Ridge, *J. Chem. Soc. Perkin Trans. 1*, 248 (2001); <https://doi.org/10.1039/B007659G>.
- I.W. Ouédraogo, M. Boulvin, R. Flammang, P. Gerbaux and Y.L. Bonzi-Coulbaly, *Molecules*, **14**, 3275 (2009); <https://doi.org/10.3390/molecules14093275>.
- A.I. Vogel, *A Textbook of Quantitative Inorganic Analysis*, Longman: London, edn. 5, pp. 228-229 (1989).
- D.C. Bradley, F. M. Abd-El Halim, R.C. Mehrotra and W. Wardlaw, *J. Chem. Soc.*, 4609 (1952); <https://doi.org/10.1039/JR9520004609>.

16. A. Chaudhary, V. Dhayal, M. Nagar, R. Bohra, S.M. Mobin and P.P. Mathur, *Polyhedron*, **30**, 821 (2011); <https://doi.org/10.1016/j.poly.2010.12.025>.
17. B. Samuel, K. Tummalapalli, P.V. Giri and M. Pathak, *Asian. J. Chem.*, **25**, 8034 (2013); <https://doi.org/10.14233/ajchem.2013.15015>.
18. M. Pathak, B. Samuel, K. Tummalapalli, P.V. Giri, S. Koppala, R. Bohra and K.P. Kim, *Adv. Mat. Res.*, **584**, 415 (2012); <https://doi.org/10.4028/www.scientific.net/AMR.584.415>.
19. S.A. Sadeek, W.H. El-Shwiniy and M.S. El-Attar, *Spectrochim. Acta Part A: Mol. Biomol. Spectrosc.*, **84**, 99 (2011); <https://doi.org/10.1016/j.saa.2011.09.010>.
20. E.Y. Tshuva and D. Peri, *Coord. Chem. Rev.*, **253**, 2098 (2009); <https://doi.org/10.1016/j.ccr.2008.11.015>.
21. N.D.R. Kumar, V.C. George, P.K. Suresh and R.A. Kumar, *Asian J. Pharm. Clin. Res.*, **5**, 189 (2012).
22. O.S. Weislow, R. Kiser, D.L. Fine, J. Bader, R.H. Shoemaker and M.R. Boyd, *J. Nat. Cancer Inst.*, **81**, 577 (1989); <https://doi.org/10.1093/jnci/81.8.577>.
23. N.C. Campanella, M. da Silva Demartini, C. Torres, E.T. de Almeida and C.M.C.P. Gouvea, *Genet. Mol. Bio.*, **35**, 159 (2012); <https://dx.doi.org/10.1590/S1415-47572012005000016>.
24. D. Peri, S. Meker, M. Shavit and E.Y. Tshuva, *Chem. Eur. J.*, **15**, 2403 (2009); <https://doi.org/10.1002/chem.200801310>.